Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:05 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Erenumab For Treatment of Hemicrania Continua
NCT04303845 · Mayo Clinic · PHASE2 · terminated · last registry update 2023-02-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “difficulty with recruitment” | – | Registry record, Mayo Clinic |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CALCRL within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-02-06Results posted on the registry: Novartis Pharmaceuticals, Erenumab (NCT04084314)
- 2024-02-05Phase 3 first posted: AbbVie, Atogepant + Placebo for Atogepant (NCT06241313)
- 2024-01-31Results posted on the registry: Antonios Likourezos, aspirin and ketamine + Nurtec (Rimegepant) (NCT04860713)
- 2024-01-09Results posted on the registry: Mayo Clinic, Erenumab (NCT03773562)
- 2023-12-14Results posted on the registry: Pfizer, Rimegepant + Placebo (NCT04574362)
- 2023-10-27Phase 3 first posted: Pfizer, Zavegepant 10 mg + Placebo - Control 1 (NCT06103734)
- 2023-10-13Results posted on the registry: Amgen, Erenumab 70 mg + Erenumab 140 mg (NCT03971071)
- 2023-09-21Results posted on the registry: Allergan, Atogepant 60 mg + Placebo (NCT04740827)
- 2023-08-14Phase 3 first posted: Pfizer, Zavegepant + Placebo (NCT05989048)
- 2023-05-31Results posted on the registry: AbbVie, Ubrogepant 100 mg + Placebo (NCT04492020)
- 2023-05-24Results posted on the registry: Allergan, Atogepant (NCT04829747)
- 2023-05-16Phase 3 first posted: AbbVie, Atogepant + Placebo for Atogepant (NCT05861427)
- 2023-04-12Phase 3 first posted: Pfizer, Rimegepant + Placebo (NCT05810038)
- 2023-03-16Results posted on the registry: Pfizer, Zavegepant (BHV-3500) (NCT04408794)
- 2023-03-16Results posted on the registry: Pfizer, Zavegepant + Placebo (NCT04571060)
- 2023-02-28Phase 3 first posted: AbbVie, Atogepant + Placebo for Atogepant (NCT05748483)
- 2023-02-14Results posted on the registry: Allergan, Atogepant 30 mg + Atogepant 60 mg (NCT03855137)
- 2023-02-03Phase 3 first posted: AbbVie, Atogepant + Placebo-Matching Atogepant (NCT05711394)
- 2023-02-01Phase 3 first posted: AbbVie, Atogepant (NCT05707949)
- 2022-10-25Results posted on the registry: Amgen, AMG334 + Oral Prophylactic (NCT03927144)
- 2022-10-13Results posted on the registry: Pfizer, Zavegepant + Zavegepant matching placebo (NCT03872453)
- 2022-10-05Results posted on the registry: Merle Diamond, Erenumab-Aooe 140 MG/ML [Aimovig] (NCT04465357)
- 2022-07-20Results posted on the registry: Amgen, Placebo + Erenumab (NCT03912337)
- 2022-07-20Also stopped (terminated): Amgen, Placebo + Erenumab (NCT03912337)
- 2022-07-14Phase 3 first posted: Teva Branded Pharmaceutical Products R&D, Inc., Fremanezumab + Placebo (NCT05458011)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision